Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $4614.00 per share for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2021-08-12
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-06-30 was $4614.00, a 150.90% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-03-31 was $4284.00, a 184.46% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2020-09-30 was $2406.00, a 141.32% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2020-06-30 was $1839.00, a 153.31% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $7907.00, a 164.45% increase from fiscal 2019.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2019 was $2990.00, a 1125.41% increase from fiscal 2018.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2018 was $244.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-06-30 | $4614.00 10-Q · filed 2021-08-12 | $8898.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $4284.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $7907.00 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $2406.00 10-Q · filed 2020-11-16 | $5751.00 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $1839.00 10-Q · filed 2021-08-12 | $3345.00 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1506.00 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $2990.00 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $997.00 10-Q · filed 2020-11-16 | $1766.00 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $726.00 10-Q · filed 2020-08-12 | $799.00 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $73.00 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $244.00 10-K · filed 2020-03-26 | |||
| 2018-09-30 | $78.00 10-Q · filed 2019-11-18 | $182.00 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |